{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:33:50Z","timestamp":1769826830834,"version":"3.49.0"},"reference-count":164,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Omicron variants have highly influenced the entire globe. It has a high rate of transmissibility, which makes its management tedious. There are various subtypes of omicron, namely BA.1, BA.2, BA.3, BA.4, and BA.5. Currently, one omicron subvariant BF.7 is also immersed in some parts of India. Further studies are required for a better understanding of the new immersing SARS-CoV-2 subvariant of the omicron. They differ in the mutation of the spike proteins, which alters their attachment to the host receptor and hence modifies their virulence and adaptability. Delta variants have a great disastrous influence on the entire world, especially in India. While overcoming it, another mutant catches the pace. The Indian population is highly affected by omicron variants. It alters the entire management and diagnosis system against COVID-19. It demanded forcemeat in the health care system, both qualitatively and quantitively, to cope with the omicron wave. The alteration in spike protein, which is the major target of vaccines, leads to varied immunization against the subvariants. The efficacy of vaccines against the new variant was questioned. Every vaccine had a different shielding effect on the new variant. The hesitancy of vaccination was a prevalent factor in India that might have contributed to its outbreak. The prevalence of omicron, monkeypox, and tomato flu shared some similarities and distinct features when compared to their influence on the Indian population. This review emphasizes the changes omicron brings with it and how the Indian health care system outrage this dangerous variant.<\/jats:p>","DOI":"10.3390\/vaccines11010160","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T02:28:44Z","timestamp":1673490524000},"page":"160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7701-8597","authenticated-orcid":false,"given":"Vivek","family":"Chavda","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-669X","authenticated-orcid":false,"given":"Pankti","family":"Balar","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-6468","authenticated-orcid":false,"given":"Dixa","family":"Vaghela","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hetvi","family":"Solanki","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akta","family":"Vaishnav","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-168X","authenticated-orcid":false,"given":"Vivek","family":"Hala","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-9066","authenticated-orcid":false,"given":"Lalitkumar","family":"Vora","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Queen\u2019s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pal, M., Berhanu, G., Desalegn, C., and Kandi, V. (2020). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus, 12.","DOI":"10.7759\/cureus.7423"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1080\/14760584.2022.2112571","article-title":"COVID-19 Vaccine Design and Vaccination Strategy for Emerging Variants","volume":"21","author":"Chavda","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mco2.110","article-title":"SARS-CoV-2 Omicron Variant: Characteristics and Prevention","volume":"2","author":"He","year":"2021","journal-title":"MedComm"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Bezbaruah, R., Deka, K., Nongrang, L., and Kalita, T. (2022). The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines, 10.","DOI":"10.3390\/vaccines10111926"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"veac064","DOI":"10.1093\/ve\/veac064","article-title":"Tracking the Turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian State (Minas Gerais) with a High-Vaccination Status","volume":"8","author":"Fonseca","year":"2022","journal-title":"Virus Evol."},{"key":"ref_6","unstructured":"(2022, December 09). Tracking SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2022.2044800","article-title":"Global Impact of Delta plus Variant and Vaccination","volume":"21","author":"Chavda","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/jmv.27717","article-title":"SARS-CoV-2 Variants and Vulnerability at the Global Level","volume":"94","author":"Chavda","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2068883","DOI":"10.1080\/21645515.2022.2068883","article-title":"Delta Variant (B.1.617.2) of SARS-CoV-2: Mutations, Impact, Challenges and Possible Solutions","volume":"18","author":"Dhawan","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14760584.2021.1976153","article-title":"Impact of the Delta Variant on Vaccine Efficacy and Response Strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shrestha, L.B., Foster, C., Rawlinson, W., Tedla, N., and Bull, R.A. (2022). Evolution of the SARS-CoV-2 Omicron Variants BA.1 to BA.5: Implications for Immune Escape and Transmission. Rev. Med. Virol., 32.","DOI":"10.1002\/rmv.2381"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41392-022-00992-2","article-title":"Tracking SARS-CoV-2 Omicron Diverse Spike Gene Mutations Identifies Multiple Inter-Variant Recombination Events","volume":"7","author":"Ou","year":"2022","journal-title":"Signal Transduct. Target."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 Variant: A New Chapter in the COVID-19 Pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., and Apostolopoulos, V. (2022). Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?. Vaccines, 10.","DOI":"10.3390\/vaccines10030367"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"961198","DOI":"10.3389\/fimmu.2022.961198","article-title":"Fast-Track Development of Vaccines for SARS-CoV-2: The Shots That Saved the World","volume":"13","author":"Chavda","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bolcato, M., Trabucco Aurilio, M., Di Mizio, G., Piccioni, A., Feola, A., Bonsignore, A., Tettamanti, C., Ciliberti, R., Rodriguez, D., and Aprile, A. (2021). The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18052484"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1080\/14760584.2022.2114900","article-title":"COVID-19 and Vaccination: Myths vs Science","volume":"21","author":"Chavda","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Feehan, J., and Apostolopoulos, V. (2021). A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals. Vaccines, 9.","DOI":"10.3390\/vaccines9060631"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ga, E., Won, Y., Hwang, J., Moon, S., Yeom, M., Lyoo, K., Song, D., Han, J., and Na, W. (2022). A COVID-19 Vaccine for Dogs Prevents Reverse Zoonosis. Vaccines, 10.","DOI":"10.3390\/vaccines10050676"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13054-020-03120-0","article-title":"Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19","volume":"24","author":"Ni","year":"2020","journal-title":"Crit. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14712598.2022.2078160","article-title":"Therapeutic Monoclonal Antibodies for COVID-19 Management: An Update","volume":"22","author":"Chavda","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jmii.2022.03.007","article-title":"Challenges of SARS-CoV-2 Omicron Variant and Appropriate Countermeasures","volume":"55","author":"Shao","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.xcrm.2021.100255","article-title":"Complete Map of SARS-CoV-2 RBD Mutations That Escape the Monoclonal Antibody LY-CoV555 and Its Cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"w30120","DOI":"10.4414\/SMW.2021.w30120","article-title":"PCR Performance in the SARS-CoV-2 Omicron Variant of Concern?","volume":"151","author":"Metzger","year":"2021","journal-title":"Swiss Med. Wkly."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance","volume":"62","author":"Chen","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"Yu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradnik, J., and Shirakawa, K. (2022). Virological Characteristics of SARS-CoV-2 BA.2 Variant. bioRxiv.","DOI":"10.1101\/2022.02.14.480335"},{"key":"ref_28","unstructured":"(2022, November 11). Omicron Subvariants BA.4 and BA.5 in India: Symptoms, Severity, Medtalks. Available online: https:\/\/www.medtalks.in\/articles\/omicron-subvariants-ba-4-and-b-a-5-in-india."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.nmni.2022.100997","article-title":"Emergence of Omicron Variant\u2019s Sublineages BA.4 and BA.5: Risks Assessment and Possible Countermeasures","volume":"48","author":"Dhawan","year":"2022","journal-title":"New Microbes New Infect."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104270","DOI":"10.1016\/j.ebiom.2022.104270","article-title":"SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern","volume":"84","author":"Aggarwal","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_31","unstructured":"(2022, November 27). Outbreak.Info SARS-CoV-2 Data Explorer. Available online: https:\/\/outbreak.info\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2022.08.009","article-title":"Knowing the New Omicron BA.2.75 Variant (\u2018Centaurus\u2019): A Simulation Study","volume":"105","author":"Zappa","year":"2022","journal-title":"Eur. J. Internal Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Karyakarte, R., Das, R., Taji, N., Yanamandra, S., Shende, S., Joshi, S., Karekar, B., Bawale, R., Tiwari, R., and Jadhav, M. (2022). An Early and Preliminary Assessment of the Clinical Severity of the Emerging SARS-CoV-2 Omicron Variants in Maharashtra, India. Cureus, 14.","DOI":"10.7759\/cureus.31352"},{"key":"ref_34","unstructured":"(2022, December 08). Omicron Subvariant\u2014BA.2.75. Narayana Health Care. Available online: https:\/\/www.narayanahealth.org\/blog\/omicron-subvariant-ba-2-75\/."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref_36","unstructured":"(2022, November 24). Anatomy of Omicron BA.1 and BA.2 Neutralizing Antibodies in COVID-19 MRNA Vaccinees. Nature Communications. Available online: https:\/\/www.nature.com\/articles\/s41467-022-31115-8."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/jmv.27626","article-title":"Emerging Evidence on Omicron (B.1.1.529) SARS-CoV-2 Variant","volume":"I94","author":"Sharma","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing Antibodies against the SARS-CoV-2 Omicron Variant BA.1 Following Homologous and Heterologous CoronaVac or BNT162b2 Vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Strasser, Z.H., Greifer, N., Hadavand, A., Murphy, S.N., and Estiri, H. (2022). Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. JAMA Netw. Open, 5.","DOI":"10.1001\/jamanetworkopen.2022.38354"},{"key":"ref_40","unstructured":"(2022, November 24). Omicron Infection Is a Poor Booster of COVID-19 Immunity | Imperial News | Imperial College London. Available online: https:\/\/www.imperial.ac.uk\/news\/237315\/omicron-infection-poor-booster-covid-19-immunity\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1056\/NEJMc2205019","article-title":"Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants","volume":"386","author":"Evans","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_42","unstructured":"(2022, November 24). What Omicron\u2019s BA.4 and BA.5 Variants Mean for the Pandemic. Available online: https:\/\/www.nature.com\/articles\/d41586-022-01730-y."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A Bivalent Omicron-Containing Booster Vaccine against COVID-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","unstructured":"(2022, December 09). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available online: https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"ref_45","unstructured":"(2022, December 08). SARS-CoV-2 Variants of Concern and Variants under Investigation, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1115071\/Technical-Briefing-45-9September2022.pdf."},{"key":"ref_46","unstructured":"(2022, December 09). How Dangerous Is the Delta Variant (B.1.617.2)?. Available online: https:\/\/asm.org\/Articles\/2021\/July\/How-Dangerous-is-the-Delta-Variant-B-1-617-2."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/s41423-021-00772-y","article-title":"Delta Variant (B.1.617.2) Sublineages Do Not Show Increased Neutralization Resistance","volume":"18","author":"Arora","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1515\/jbcpp-2021-0251","article-title":"The \u201cDelta Plus\u201d COVID-19 Variant Has Evolved to Become the next Potential Variant of Concern: Mutation History and Measures of Prevention","volume":"33","author":"Rahman","year":"2021","journal-title":"J. Basic Clin. Physiol. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jmv.27526","article-title":"Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike Protein","volume":"94","author":"Kumar","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102715","DOI":"10.1016\/j.jaut.2021.102715","article-title":"Evolutionary Analysis of the Delta and Delta Plus Variants of the SARS-CoV-2 Viruses","volume":"124","author":"Kannan","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_52","unstructured":"(2022, December 09). Coronavirus Delta Variant: 8 Things You Should Know about This COVID-19 Strain. UC Davis Health. Available online: https:\/\/health.ucdavis.edu\/coronavirus\/covid-19-information\/delta-variant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/clinpract11020044","article-title":"Analysis of COVID-19 on Diagnosis, Vaccine, Treatment, and Pathogenesis with Clinical Scenarios","volume":"11","author":"Tellez","year":"2021","journal-title":"Clin. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.amjcard.2015.12.060","article-title":"Impact of Physical Inactivity on Mortality in Patients with Heart Failure","volume":"117","author":"Doukky","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20210900","DOI":"10.1098\/rsif.2021.0900","article-title":"COVID-19 Pandemic Dynamics in India, the SARS-CoV-2 Delta Variant, and Implications for Vaccination","volume":"19","author":"Yang","year":"2021","journal-title":"J. R. Soc. Interface"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"n1445","DOI":"10.1136\/bmj.n1445","article-title":"COVID-19: Delta Variant Is Now UK\u2019s Most Dominant Strain and Spreading through Schools","volume":"373","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"key":"ref_57","unstructured":"(2022, December 09). Viral Infection and Transmission in a Large, Well-Traced Outbreak Caused by the SARS-CoV-2 Delta Variant, MedRxiv. Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.07.07.21260122v2."},{"key":"ref_58","unstructured":"(2022, December 09). World Health Organization (WHO). Available online: https:\/\/www.who.int."},{"key":"ref_59","unstructured":"(2022, December 09). India COVID\u2014Coronavirus Statistics-Worldometer. Available online: https:\/\/www.worldometers.info\/coronavirus\/country\/india\/."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_61","unstructured":"(2022, December 09). Eurosurveillance. Increased Transmissibility and Global Spread of SARS-CoV-2 Variants of Concern as at June 2021. Available online: https:\/\/www.eurosurveillance.org\/content\/10.2807\/1560-7917.ES.2021.26.24.2100509."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41586-021-04069-y","article-title":"Genomic Reconstruction of the SARS-CoV-2 Epidemic in England","volume":"600","author":"Sanderson","year":"2021","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijid.2021.05.040","article-title":"SARS-CoV-2 Seroprevalence among the General Population and Healthcare Workers in India, December 2020\u2013January 2021","volume":"108","author":"Murhekar","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_64","unstructured":"(2022, December 09). Genome Sequencing by INSACOG Shows Variants of Concern and a Novel Variant in India, Available online: https:\/\/pib.gov.in\/Pressreleaseshare.aspx?PRID=1707177."},{"key":"ref_65","unstructured":"(2022, December 09). Lessons from SARS-CoV-2 in India: A Data-Driven Framework for Pandemic Resilience. Science Advances. Available online: https:\/\/www.science.org\/doi\/10.1126\/sciadv.abp8621."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.jve.2021.100054","article-title":"Recent Advances in SARS-CoV-2 Spike Protein and RBD Mutations Comparison between New Variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India)","volume":"7","author":"Sanches","year":"2021","journal-title":"J. Virus Erad."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The Significant Immune Escape of Pseudotyped SARS-CoV-2 Variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_68","unstructured":"(2022, December 09). India\u2019s First Omicron Cases Detected in Karnataka. Available online: https:\/\/www.hindustantimes.com\/india-news\/indias-first-omicron-cases-detected-in-karnataka-101638445884205.html."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 Vaccine Acceptance and Hesitancy in Low- and Middle-Income Countries","volume":"27","author":"Warren","year":"2021","journal-title":"Nat. Med."},{"key":"ref_70","unstructured":"(2022, December 09). CDC Coronavirus Disease 2019 (COVID-19), Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/index.html."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.28991\/SciMedJ-2021-0304-10","article-title":"A Mini Review on SARS-CoV-19-2 Omicron Variant (B. 1.1. 529)","volume":"3","author":"Ettaboina","year":"2021","journal-title":"SciMedicine J."},{"key":"ref_72","unstructured":"(2022, December 09). Livemint Omicron Was Less Severe in India Because of These 2 Reasons, Finds Study. Available online: https:\/\/www.livemint.com\/science\/health\/omicron-was-less-severe-in-india-because-of-these-2-reasons-finds-study-read-here-11644411033886.html."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41392-021-00852-5","article-title":"SARS-CoV-2 Omicron Strain Exhibits Potent Capabilities for Immune Evasion and Viral Entrance","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target."},{"key":"ref_74","unstructured":"(2022, December 09). Delhi: Genome Sequencing Reveals Omicron Variant in 38% Samples from City. Available online: https:\/\/www.indiatoday.in\/coronavirus-outbreak\/story\/delhi-genome-sequencing-omicron-variant-in-samples-1893918-2021-12-29."},{"key":"ref_75","unstructured":"(2022, December 09). India News, Omicron Found in Delhi\u2019s 65% Samples Whose Genome Sequencing Report Came out Between Jan 1 and 3, LatestLY. Available online: https:\/\/www.latestly.com\/agency-news\/india-news-omicron-found-in-delhis-65-samples-whose-genome-sequencing-report-came-out-between-jan-1-and-3-3225440.html."},{"key":"ref_76","unstructured":"(2022, December 09). Mumbai\u2019s Sixth Genome Sequencing: Omicron Found in 2 per Cent Samples. Available online: https:\/\/www.mid-day.com\/mumbai\/mumbai-news\/article\/mumbais-sixth-genome-sequencing-omicron-found-in-2-per-cent-samples-23205256."},{"key":"ref_77","unstructured":"(2022, December 09). Genome Sequencing Shows Omicron Variant Predominant Strain in COVID Cases in Mumbai. Cities News, The Indian Express. Available online: https:\/\/indianexpress.com\/article\/cities\/mumbai\/mumbai-genome-sequencing-omicron-variant-covid-19-7800080\/."},{"key":"ref_78","unstructured":"INSACOG (2022, December 09). Department of Biotechnology, Available online: https:\/\/dbtindia.gov.in\/insacog."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14787210.2022.2036605","article-title":"Containment Strategies for COVID-19 in India: Lessons from the Second Wave","volume":"20","author":"Asrani","year":"2022","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"708224","DOI":"10.3389\/fpubh.2021.708224","article-title":"Strategies for COVID-19 Epidemiological Surveillance in India: Overall Policies Till June 2021","volume":"9","author":"Ghosh","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102350","DOI":"10.1016\/j.ajp.2020.102350","article-title":"Neuropsychiatric Manifestations of COVID-19 and Possible Pathogenic Mechanisms: Insights from Other Coronaviruses","volume":"54","author":"Banerjee","year":"2020","journal-title":"Asian J. Psychiatr."},{"key":"ref_82","unstructured":"(2022, December 09). Archive - Diagnostic Kit Evaluation, Available online: https:\/\/www.icmr.gov.in\/arcckitevaluation.html."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bazargan, M., Elahi, R., and Esmaeilzadeh, A. (2022). OMICRON: Virology, Immunopathogenesis, and Laboratory Diagnosis. J. Gene Med., 24.","DOI":"10.1002\/jgm.3435"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1002\/jcp.29804","article-title":"The Outlook for Diagnostic Purposes of the 2019-novel Coronavirus Disease","volume":"235","author":"Tahmasebi","year":"2020","journal-title":"J. Cell Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"041506","DOI":"10.1063\/5.0021554","article-title":"Evaluation of Current Diagnostic Methods for COVID-19","volume":"4","author":"Alpdagtas","year":"2020","journal-title":"APL Bioeng."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1473-3099(21)00146-8","article-title":"Diagnostic Performance of Different Sampling Approaches for SARS-CoV-2 RT-PCR Testing: A Systematic Review and Meta-Analysis","volume":"21","author":"Tsang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Tahan, S., Parikh, B.A., Droit, L., Wallace, M.A., Burnham, C.-A.D., and Wang, D. (2021). SARS-CoV-2 E Gene Variant Alters Analytical Sensitivity Characteristics of Viral Detection Using a Commercial Reverse Transcription-PCR Assay. J. Clin. Microbiol., 59.","DOI":"10.1128\/JCM.00075-21"},{"key":"ref_88","unstructured":"(2022, December 09). A Simple and Quick PCR Based Method for Detection of Omicron Variant of SARS-CoV-2 | MedRxiv. Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.20.21268053v1.full."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41587-020-0513-4","article-title":"CRISPR-Cas12-Based Detection of SARS-CoV-2","volume":"38","author":"Broughton","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/jmv.26889","article-title":"Development and Application of Sensitive, Specific, and Rapid CRISPR-Cas13-Based Diagnosis","volume":"93","author":"Zhu","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/07853890.2022.2031274","article-title":"Emerging COVID-19 Variants and Their Impact on SARS-CoV-2 Diagnosis, Therapeutics and Vaccines","volume":"54","author":"Fernandes","year":"2022","journal-title":"Ann. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3892\/ijmm.2021.4933","article-title":"Current and Innovative Methods for the Diagnosis of COVID-19 Infection (Review)","volume":"47","author":"Falzone","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Di Domenico, M., De Rosa, A., and Boccellino, M. (2021). Detection of SARS-CoV-2 Proteins Using an ELISA Test. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040698"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s10096-021-04203-8","article-title":"Automated Western Immunoblotting Detection of Anti-SARS-CoV-2 Serum Antibodies","volume":"40","author":"Edouard","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Wratil, P.R., Stern, M., Priller, A., Willmann, A., Almanzar, G., Vogel, E., Feuerherd, M., Cheng, C.-C., Yazici, S., and Christa, C. (2022). Three Exposures to the Spike Protein of SARS-CoV-2 by Either Infection or Vaccination Elicit Superior Neutralizing Immunity to All Variants of Concern. Nat. Med., 28.","DOI":"10.1038\/s41591-022-01715-4"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/d41586-021-03672-3","article-title":"Omicron Likely to Weaken COVID Vaccine Protection","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_99","unstructured":"U.S. Food & Drug (2022, December 09). Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization among High-Risk Patients with Mild to Moderate Coronavirus Disease-19","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101989","DOI":"10.1016\/j.tmaid.2021.101989","article-title":"AZD1222 (Covishield) Vaccination for COVID-19: Experiences, Challenges, and Solutions in Nepal","volume":"40","author":"Sah","year":"2021","journal-title":"Travel. Med. Infect. Dis."},{"key":"ref_103","unstructured":"(2022, December 09). Bharat Biotech-Vaccines & Bio-Therapeutics Manufacturer in India. Available online: https:\/\/www.bharatbiotech.com\/."},{"key":"ref_104","first-page":"614","article-title":"New COVID-19 Vaccine Aims to Increase Global Vaccine Access","volume":"327","author":"Kuehn","year":"2022","journal-title":"JAMA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","article-title":"Immunogenic Potential of DNA Vaccine Candidate, ZyCoV-D against SARS-CoV-2 in Animal Models","volume":"39","author":"Dey","year":"2021","journal-title":"Vaccine"},{"key":"ref_106","unstructured":"(2022, December 09). Safety and Immunogenicity of a DNA SARS-CoV-2 Vaccine (ZyCoV-D): Results of an Open-Label, Non-Randomized Phase I Part of Phase I\/II Clinical Study by Intradermal Route in Healthy Subjects in India-EClinicalMedicine. Available online: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(21)00300-X\/fulltext."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"101027","DOI":"10.1016\/j.eclinm.2021.101027","article-title":"ROCCA Observational Study: Early Results on Safety of Sputnik V Vaccine (Gam-COVID-Vac) in the Republic of San Marino Using Active Surveillance","volume":"38","author":"Montalti","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100359","DOI":"10.1016\/j.xcrm.2021.100359","article-title":"Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS-CoV-2 after a Single Dose","volume":"2","author":"Rossi","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s15010-022-01759-1","article-title":"Implication of the Emergence of the Delta (B.1.617.2) Variants on Vaccine Effectiveness","volume":"50","author":"Koritala","year":"2022","journal-title":"Infection"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/sjhs.sjhs_42_22","article-title":"Recent Update on Treatment and Preventive Modalities for COVID-19 Omicron Variant (B.1.1.529) in India: A Comprehensive Review","volume":"11","author":"Inder","year":"2022","journal-title":"Saudi J. Health Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7774\/cevr.2022.11.2.184","article-title":"Nasal Vaccine as a Booster Shot: A Viable Solution to Restrict Pandemic?","volume":"11","author":"Meenakshi","year":"2022","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1140\/epjp\/s13360-021-02321-y","article-title":"Omicron: A Mysterious Variant of Concern","volume":"137","author":"Gowrisankar","year":"2022","journal-title":"Eur. Phys. J. Plus."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jmv.27541","article-title":"OMICRON (B.1.1.529): A New SARS-CoV-2 Variant of Concern Mounting Worldwide Fear","volume":"94","author":"Thakur","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_114","unstructured":"(2022, December 09). COVID-19 Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant, NEJM. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2119451."},{"key":"ref_115","unstructured":"(2022, December 09). Oxford\/AstraZeneca: Vaxzevria\u2013COVID19 Vaccine Tracker. Available online: https:\/\/covid19.trackvaccines.org\/vaccines\/4\/."},{"key":"ref_116","unstructured":"(2022, December 09). More Than 12.7 Billion Shots Given: COVID-19 Vaccine Tracker. Available online: https:\/\/www.bloomberg.com\/graphics\/covid-vaccine-tracker-global-distribution\/."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_118","unstructured":"(2022, December 09). The Pfizer BioNTech (BNT162b2) COVID-19 Vaccine: What You Need to Know. Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Serum Institute of India (2022, December 09). ChAdOx1 NCoV-19 Corona Virus Vaccine (Recombinant)-COVISHIELD. Available online: https:\/\/www.seruminstitute.com\/product_covishield.php.","DOI":"10.1016\/j.nerep.2021.100006"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/j.mjafi.2021.06.032","article-title":"COVISHIELD (AZD1222) VaccINe Effectiveness among Healthcare and Frontline Workers of INdian Armed Forces: Interim Results of VIN-WIN Cohort Study","volume":"77","author":"Ghosh","year":"2021","journal-title":"Med. J. Armed India"},{"key":"ref_121","unstructured":"U.S. Food & Drug (2022, December 08). Moderna COVID-19 Vaccines. FDA, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/moderna-covid-19-vaccines."},{"key":"ref_122","unstructured":"(2022, December 09). The Moderna COVID-19 (MRNA-1273) Vaccine: What You Need to Know. Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S1473-3099(22)00692-2","article-title":"BNT162b2 Vaccine Effectiveness against SARS-CoV-2 Omicron BA.4 and BA.5","volume":"22","author":"Tartof","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., and O\u2019Connell, A.-M. (2021). Effectiveness of COVID-19 Vaccines against the Omicron (B.1.1.529) Variant of Concern. medRxiv.","DOI":"10.1101\/2021.12.14.21267615"},{"key":"ref_125","unstructured":"(2022, December 09). COVID-19 Vaccine Tracker and Landscape. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Trabucco Aurilio, M., Mennini, F.S., Gazzillo, S., Massini, L., Bolcato, M., Feola, A., Ferrari, C., and Coppeta, L. (2021). Intention to Be Vaccinated for COVID-19 among Italian Nurses during the Pandemic. Vaccines, 9.","DOI":"10.3390\/vaccines9050500"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Dhalaria, P., Arora, H., Singh, A.K., Mathur, M., and S., A.K. (2022). COVID-19 Vaccine Hesitancy and Vaccination Coverage in India: An Exploratory Analysis. Vaccines, 10.","DOI":"10.3390\/vaccines10050739"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in Ensuring Global Access to COVID-19 Vaccines: Production, Affordability, Allocation, and Deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"100495","DOI":"10.1016\/j.eclinm.2020.100495","article-title":"Determinants of COVID-19 Vaccine Acceptance in the US","volume":"26","author":"Malik","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Kreps, S., Prasad, S., Brownstein, J.S., Hswen, Y., Garibaldi, B.T., Zhang, B., and Kriner, D.L. (2020). Factors Associated With US Adults\u2019 Likelihood of Accepting COVID-19 Vaccination. JAMA Netw. Open., 3.","DOI":"10.1001\/jamanetworkopen.2020.25594"},{"key":"ref_131","unstructured":"(2022, December 09). Global Attitudes: COVID-19 Vaccines. Available online: https:\/\/www.ipsos.com\/en-ro\/global-attitudes-covid-19-vaccine-january-2021."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-020-1124-9","article-title":"A Global Survey of Potential Acceptance of a COVID-19 Vaccine","volume":"27","author":"Lazarus","year":"2021","journal-title":"Nat. Med."},{"key":"ref_133","unstructured":"(2022, December 09). Overview of Public Health and Social Measures in the Context of COVID-19. Available online: https:\/\/www.who.int\/publications-detail-redirect\/overview-of-public-health-and-social-measures-in-the-context-of-covid-19."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1473-3099(21)00201-2","article-title":"Lack of Detail in Population-Level Data Impedes Analysis of SARS-CoV-2 Variants of Concern and Clinical Outcomes","volume":"21","author":"Ong","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/JOM.0000000000002205","article-title":"Vaccine Hesitancy Against SARS-CoV-2 in Health Personnel of Northeastern Mexico and Its Determinants","volume":"63","year":"2021","journal-title":"J. Occup. Environ. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11357-021-00500-4","article-title":"Omicron Variant of the SARS-CoV-2: A Quest to Define the Consequences of Its High Mutational Load","volume":"44","author":"Quarleri","year":"2022","journal-title":"GeroScience"},{"key":"ref_137","unstructured":"(2022, December 08). Omicron Symptoms: Here\u2019s How They Differ from Other Variants. NBC Chicago. Available online: https:\/\/www.nbcchicago.com\/news\/local\/omicron-symptoms-heres-how-they-differ-from-other-variants\/2723960\/."},{"key":"ref_138","unstructured":"(2022, December 08). CDCMMWR SARS-CoV-2 B.1.1.529 (Omicron) Variant\u2014United States, December 1\u20138, 2021, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8675659\/."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.lansea.2022.100063","article-title":"Monkeypox Reported in India\u2013South East Asia Region: Health and Economic Challenges","volume":"4","author":"Sah","year":"2022","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"ref_140","unstructured":"(2022, October 31). CDC Monkeypox in the U.S, Available online: https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/index.html."},{"key":"ref_141","unstructured":"(2022, December 08). Guidelines for Management of Monkeypox Disease.Pdf, Available online: https:\/\/main.mohfw.gov.in\/sites\/default\/files\/Guidelines%20for%20Management%20of%20Monkeypox%20Disease.pdf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(22)01789-5","article-title":"Evolutionary Consequences of Delaying Intervention for Monkeypox","volume":"400","author":"Johnson","year":"2022","journal-title":"Lancet"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s41591-022-02036-2","article-title":"Addendum: Phylogenomic Characterization and Signs of Microevolution in the 2022 Multi-Country Outbreak of Monkeypox Virus","volume":"28","author":"Isidro","year":"2022","journal-title":"Nat. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ana.26473","article-title":"An Overview of Monkeypox Virus and Its Neuroinvasive Potential","volume":"92","author":"Pastula","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1093\/cid\/ciz1188","article-title":"Early Evidence of Inactivated Enterovirus 71 Vaccine Impact Against Hand, Foot, and Mouth Disease in a Major Center of Ongoing Transmission in China, 2011\u20132018: A Longitudinal Surveillance Study","volume":"71","author":"Head","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"o2101","DOI":"10.1136\/bmj.o2101","article-title":"Reports of \u201cTomato Flu\u201d Outbreak in India Are Not Due to New Virus, Say Doctors","volume":"378","author":"Thiagarajan","year":"2022","journal-title":"BMJ"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1017\/S0950268809991555","article-title":"Human Enterovirus 71 and Hand, Foot and Mouth Disease","volume":"138","author":"Wong","year":"2010","journal-title":"Epidemiol. Infect."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"123","DOI":"10.24018\/ejmed.2022.4.3.1376","article-title":"The Omicron Wave in India, Mumbai, and Delhi: Prevalence and Pathogenicity","volume":"4","author":"Shervani","year":"2022","journal-title":"Eur. J. Med. Health Sci."},{"key":"ref_149","first-page":"459","article-title":"Clinico-Epidemiological Features of Monkeypox Patients with an Animal or Human Source of Infection","volume":"66","author":"Jezek","year":"1988","journal-title":"Bull. World Health Organ."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"(2022, November 27). Clinical Characteristics of Human Monkeypox, and Risk Factors for Severe Disease. Clinical Infectious Diseases. Oxford Academic. Available online: https:\/\/academic.oup.com\/cid\/article\/41\/12\/1742\/344953.","DOI":"10.1086\/498115"},{"key":"ref_151","unstructured":"Taneja, P., and News, I.T. (2022, November 27). HFMD Cases Increase Rapidly in Kids; Know Causes, Symptoms, and Remedies from Dr. Neha Srivastava. Available online: https:\/\/www.indiatvnews.com\/health\/hfmd-cases-increase-rapidly-in-kids-know-causes-symptoms-and-remedies-from-dr-neha-srivastava-2022-10-03-813453."},{"key":"ref_152","unstructured":"(2022, November 27). Omicron Variant of COVID 19 - Symptoms, Treatment and Update. Available online: https:\/\/www.pacehospital.com\/omicron-variant-of-covid-19."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-022-01742-y","article-title":"Prevention and Treatment of Monkeypox","volume":"82","author":"Rizk","year":"2022","journal-title":"Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jiph.2022.10.012","article-title":"Monkeypox Treatment: Is Tecovirimat the Answer?","volume":"15","author":"Niaz","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_155","unstructured":"(2022, November 27). Usefulness of Low-Level Laser for Control of Painful Stomatitis in Patients with Hand-Foot-and-Mouth Disease. Journal of Clinical Laser Medicine & Surgery. Available online: https:\/\/www.liebertpub.com\/doi\/abs\/10.1089\/104454703322650176."},{"key":"ref_156","unstructured":"(2022, December 08). Management of Hand Foot Mouth Disease (HFMD) in Health Care Settings, Available online: https:\/\/www.chp.gov.hk\/files\/pdf\/sceifd_management_of_hfmd_in_health_care_settings.pdf."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.15585\/mmwr.mm7137a4","article-title":"Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods\u2014United States, April 2020\u2013June 2022","volume":"71","author":"Adjei","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_158","unstructured":"(2022, November 28). How Deadly Is Monkeypox? What Scientists Know. Available online: https:\/\/www.nature.com\/articles\/d41586-022-02931-1."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"11662","DOI":"10.1038\/s41598-019-48259-1","article-title":"The Clinical and Epidemiological Study of Children with Hand, Foot, and Mouth Disease in Hunan, China from 2013 to 2017","volume":"9","author":"Qiu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"127204","DOI":"10.1016\/j.micres.2022.127204","article-title":"Omicron Variant: Current Insights and Future Directions","volume":"265","author":"Rana","year":"2022","journal-title":"Microbiol. Res."},{"key":"ref_161","unstructured":"(2022, December 24). Explained: Can a RT-PCR Test Detect Infection with Omicron Variant of COVID-19? Explained News, The Indian Express. Available online: https:\/\/indianexpress.com\/article\/explained\/can-an-rt-pcr-test-detect-infection-with-omicron-7648176\/."},{"key":"ref_162","unstructured":"(2022, December 24). Omicron BF.7: Cases of Highly Infectious Strain Rise in India; Experts on Symptoms, Precautions and Fresh Wave. Available online: https:\/\/www.hindustantimes.com\/lifestyle\/health\/omicron-bf-7-cases-of-highly-infectious-strain-rise-in-india-experts-on-symptoms-precautions-and-fresh-wave-101671627215813.html."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal Vaccines for SARS-CoV-2: From Challenges to Potential in COVID-19 Management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Vihol, D.R., Solanki, H.K., and Apostolopoulos, V. (2022). The Vaccine World of COVID-19: India\u2019s Contribution. Vaccines, 10.","DOI":"10.3390\/vaccines10111943"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/1\/160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:03:26Z","timestamp":1760119406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/1\/160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":164,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["vaccines11010160"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11010160","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}